India Remains With Five Other Asia Nations On USTR's 'Priority Watch List'
This article was originally published in PharmAsia News
The U.S. Trade Representative office issued a new intellectual-property "priority watch list," which retains six Asian and Middle East nations on the list, some for pharmaceutical reasons, dropping Israel.
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.